A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study.
BRAF V600E
EGFR
HPLC-MS/MS
Lifirafenib
Pharmacokinetics
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
20 Mar 2019
20 Mar 2019
Historique:
received:
04
11
2018
accepted:
23
12
2018
pubmed:
2
1
2019
medline:
2
7
2019
entrez:
2
1
2019
Statut:
ppublish
Résumé
Lifirafenib (BGB-283), a dual inhibitor trageting BRAF kinase and EGFR, showed favorable efficacy and safety in treating patients with different cancer types harboring mutations in BRAF, KRAS and NRAS. In order to support the clinical pharmacokinetic study, a sensitive high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated to quantify lifirafenib concentration in human plasma and urine. Plasma samples were purified using protein precipitation. Urine samples were pre-treated by adding tween 80 with the purpose of preventing non-specific adsorption, then extracted by centrifugation. Chromatographic separation was achieved on Phenomenex Luna C
Identifiants
pubmed: 30599278
pii: S0731-7085(18)32481-6
doi: 10.1016/j.jpba.2018.12.038
pii:
doi:
Substances chimiques
BGB-283
0
Benzimidazoles
0
Naphthyridines
0
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-29Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.